Czechia· CZ-0238538

LIBTAYO

A cemiplimab product containing cemiplimab, registered in Czechia by Regeneron Ireland Designated Activity Company, Dublin. The same ATC class is registered in 12 of our 19 countries.

ATC L01FF06

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedLIBTAYOATCL01FF06REGISTER NO.CZ-0238538PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Cemiplimab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF06 (cemiplimab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Cemiplimab · ATC L01FF06

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
CEMIPLIMAB
Manufacturer
Regeneron Ireland Designated Activity Company, Dublin
Country
Czechia (CZ)
ATC code
L01FF06
ATC class
Cemiplimab
Defined daily dose
16.7 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0238538
    1X7ML
    CZK 117295.23

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

17 interactions on record for cemiplimab.

Graded by severity as the source publishes them — 17 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cemiplimab · interactions on record

17 records

  • 17 moderate

Most severe, free to view

  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • BetamethasoneA07EA04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4dad31a0-5450-4081-bac8-e5a17b62f189
GET /v1/drugs/4dad31a0-5450-4081-bac8-e5a17b62f189?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF CNC SOL",
  "source": "sukl",
  "strength": "350MG",
  "pack_size": "1X7ML",
  "substance": "CEMIPLIMAB",
  "cz_kod_sukl": "0238538",
  "product_type": "BT",
  "substance_codes": "21912",
  "registration_state": "R",
  "registration_number": "EU/1/19/1376/001"
}

See everything about cemiplimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.